Recent Updates
Recently added Catalysts

BCT197

Phase 2

Chronic Obstructive Pulmonary Disease | Small molecule | Other |Mereo BioPharma Group plc|Last Updated: Mar 20, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment183
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01332097Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an ExacerbationPHASE2 COMPLETED 183Mar 1, 2011May 1, 2013Mar 20, 2023 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
BCT197DRUG -
Prednisone placeboDRUGcapsules
BCT197 placeboDRUGcapsules
PrednisoneDRUGcapsules
Unlock Study Design Details